Hereditary Angioedema Attacks Resolve Faster and Are Shorter after Early Icatibant Treatment
Open Access
- 4 February 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (2), e53773
- https://doi.org/10.1371/journal.pone.0053773
Abstract
Attacks of hereditary angioedema (HAE) are unpredictable and, if affecting the upper airway, can be lethal. Icatibant is used for physician- or patient self-administered symptomatic treatment of HAE attacks in adults. Its mode of action includes disruption of the bradykinin pathway via blockade of the bradykinin B2 receptor. Early treatment is believed to shorten attack duration and prevent severe outcomes; however, evidence to support these benefits is lacking. To examine the impact of timing of icatibant administration on the duration and resolution of HAE type I and II attacks. The Icatibant Outcome Survey is an international, prospective, observational study for patients treated with icatibant. Data on timings and outcomes of icatibant treatment for HAE attacks were collected between July 2009–February 2012. A mixed-model of repeated measures was performed for 426 attacks in 136 HAE type I and II patients. Attack duration was significantly shorter in patients treated pppp2 receptor with icatibant, particularly within the first hour of attack onset, significantly reduced attack duration and time to attack resolution.This publication has 18 references indexed in Scilit:
- Hereditary angioedema treatment options: The availability of new therapiesAnnals of Medicine, 2012
- Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trialAnnals of Allergy, Asthma & Immunology, 2011
- Evidence‐based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working GroupAllergy, 2011
- Home therapy with intravenous human C1‐inhibitor in children and adolescents with hereditary angioedemaTransfusion, 2011
- Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary AngioedemaThe New England Journal of Medicine, 2010
- The bradykinin-forming cascade and its role in hereditary angioedemaAnnals of Allergy, Asthma & Immunology, 2010
- Studies of the mechanisms of bradykinin generation in hereditary angioedema plasmaAnnals of Allergy, Asthma & Immunology, 2008
- Treatment of skin swellings with C1‐inhibitor concentrate in patients with hereditary angio‐oedemaAllergy, 2008
- Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiencyJournal of Allergy and Clinical Immunology, 2006
- Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedemaTransfusion, 2005